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Accurate definition of genetic mutations causing Duchenne 
muscular dystrophy (DMD) has always been relevant in order 
to provide genetic counseling to patients and families, and helps 
to establish the prognosis in the case where the distinction be-
tween Duchenne, Becker, or intermediate muscular dystrophy 
is not obvious. As molecular treatments aimed at dystrophin 
restoration in DMD are increasingly available as commercial-
ized drugs or within clinical trials, genetic diagnosis has become 
an indispensable tool in order to determine eligibility for these 
treatments. DMD patients in which multiplex ligation-depend-
ent probe amplification (MLPA) or similar techniques show a 
deletion suitable to exon skipping of exons 44, 45, 51, or 53, may 
be currently treated with AONs targeting these exons, in the 
context of clinical trials, or, as is the case for exon 51 skipping 
in the United States, with the first commercialized drug (etep-
lirsen). Patients who test negative at MLPA, but in whom DMD 
gene sequencing shows a nonsense mutation, may be amenable 
for treatment with stop codon readthrough compounds such as 
ataluren. Novel molecular approaches such as CRISPR-Cas9 
targeting of specific DMD mutations are still in the preclinical 
stages, but appear promising. In conclusion, an accurate genetic 
diagnosis represents the entrance into a new scenario of person-
alized medicine in DMD.
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Introduction
In 1987, the discovery that Duchenne muscular dys-
trophy (DMD) is caused by the absence of the protein 
dystrophin in skeletal muscle fibers (1) first provided a 
rationale for molecular treatments, aimed at restoring 
dystrophin expression. Shortly thereafter, the discovery 
that Becker muscular dystrophy (BMD) is a milder allelic 
form of dystrophinopathy, in which dystrophin is present 
but qualitatively altered and quantitatively reduced (2) 
suggested that clinical benefit may be provided to DMD 
patients, even with partial restoration of dystrophin ex-
pression. Despite the hope stirred by these seminal dis-
coveries, after three decades such molecular treatments 
are not yet widely available to DMD patients. In fact, for-
midable obstacles still stand in the way of the translation 
of dystrophin-restoring treatments from proof-of-concept 
experiments to clinical trials and everyday clinical prac-
tice: for instance, because of several genetic and environ-
mental factors, there is considerable variability in disease 
progression , which has made the design and interpreta-
tion of clinical trials more challenging (3, 4). Neverthe-
less, several molecular therapies for DMD have reached 
advanced stages of clinical experimentation, and the first 
drugs have recently reached the market through acceler-
ated and provisional regulatory approvals (5, 6). 
In the complex and swiftly changing scenario of ex-
perimental treatments for DMD, the expression “molecu-
lar therapy” requires a more precise definition. Dystro-
phin restoration may be achieved in two different ways: 
through genetic therapies, i.e. delivery of new genetic 
material, that is not naturally present in the patient’s cells, 
such as a functioning copy of the DMD gene or transcript; 
or through molecular therapies, i.e. small or larger mol-
ecules (i.e. oligonucleotides, enzymes), that interact with 
the patients’ own genetic material and transcription/trans-
lation machinery to restore the expression of viable dys-
trophin. Here, we intend to focus on molecular therapies, 
mainly for two reasons: first, molecular therapies have 
reached more advanced stages in human experimenta-
tion than genetic therapies for DMD, and are therefore 
of more immediate interest to neuromuscular clinicians; 
and second, they highlight the importance of reaching a 
well-defined molecular diagnosis, at the genomic level, 
in DMD. In fact, while genetic therapies would theoreti-
cally benefit any DMD patient, molecular therapies are an 
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example of personalized therapies, as they are expected 
to work only in those patients who harbor specific muta-
tions, targeted by the molecule of choice.
We will first briefly review the current standards in 
molecular diagnosis of DMD, and then the main molecu-
lar treatment strategies accessible to patients with differ-
ent identified mutations: exon skipping through antisense 
oligonucleotides (AONs), and readthrough of premature 
termination codons through the small molecule ataluren. 
Recently, the prospect of editing patients’ genomes using 
the CRISPR-Cas9 technology has opened a new exciting 
perspective in this field. 
Genetic diagnosis of DMD
Typically, the diagnosis of DMD may be established 
based on the clinical picture and the finding of absent dys-
trophin expression in muscle by immunohistochemistry 
and/or immunoblot (7). However, internationally adopted 
guidelines (8, 9) indicate that an accurate characterization 
of the causative mutation at the genomic level is of para-
mount importance in order to provide genetic counseling 
to the family, establish genotype-phenotype correlations 
and prognosis, and, as we will show in the next para-
graphs, assess eligibility for novel molecular treatments. 
The first molecular assay to be requested when DMD is 
suspected should be quantitative, i.e. provide a measure 
of the copy number of genomic regions corresponding to 
each of the 79 DMD exons. In fact, about 60 to 70% of 
DMD-causing mutations are large rearrangements (dele-
tions or duplications) including one or more exons (10). 
These are readily identified in both affected males and 
female carriers by multiplex ligation-dependent probe 
amplification (MLPA) (11). In the case of single-exon 
deletions, results should be confirmed by an independent 
technique, as some small mutations may prevent probe 
hybridization and be misinterpreted as deletions of the 
corresponding exons. Alternative quantitative techniques 
include multiplex PCR and competitive genomic hybrid-
ization (CGH) arrays. Whenever quantitative assays can-
not completely characterize the mutation, PCR amplifi-
cation and sequencing of the coding DMD regions and 
flanking nucleotides allows the identification of single 
nucleotide substitutions, small sub-exonic rearrange-
ments, and canonic splice-site mutations. While classic 
Sanger sequencing is still widely used, next generation 
sequencing (NGS) approaches are becoming increas-
ingly accessible (9). In rare cases in which no mutation 
can be identified by sequencing of genomic DNA cod-
ing regions, DMD mRNA may be isolated from skeletal 
muscle tissue (either archived from a previous diagnostic 
biopsy, or obtained specifically for this purpose), reverse-
transcribed to cDNA, and sequenced. The localization of 
sequence anomalies in the transcript may point to deep 
intronic causative mutations that may be identified by tar-
geted Sanger sequencing of intronic gDNA regions, or 
by NGS. The systematic application of this workflow in 
DMD patients (illustrated in Fig. 1) leads to the identifi-
cation of a clear pathogenetic mutation in the vast major-
ity of cases.
Exon skipping with antisense 
oligonucleotides
The rationale for “exon skipping” is based on several 
facts: in about two thirds of cases, DMD is caused by 
large deletions involving one or more exons, and disrupt-
ing the DMD open reading frame (ORF); on the contrary, 
deletions that respect the ORF cause the milder allelic 
disease BMD (12); because of the DMD genomic struc-
ture, it is often possible to restore the ORF of an out-of-
frame deletion by splicing out just one exon, adjacent to 
the deletion borders at the 5’ or 3’ side, from the mature 
mRNA. Therefore, by targeting and inactivating specific 
exon splicing signals in the pre-mRNA with sequence-
specific AONs, it is possible to obtain an internally de-
leted, yet in-frame DMD transcript, which is similar to 
transcripts naturally observed in BMD patients. These 
transcripts may then be translated into a viable, albeit 
internally deleted and quantitatively reduced, dystrophin 
protein, hopefully shifting the patient’s clinical picture 
towards the milder BMD phenotype. The application of 
AON treatments to DMD and other genetic conditions 
became technically possible in the early 2000s, with the 
invention of chemically modified nucleotide backbones, 
which resisted to nucleases and had a favourable phar-
macokinetic and pharmacodynamic profile in humans. 
These were 2’-O-methyl RNA phosphorothioate AONs 
(administered subcutaneously) and morpholino AONs 
(administered intravenously) (13). For both chemistries, 
first-in-human studies with local intramuscular injections 
of AONs showed promising dystrophin restoration in 
biopsies of injected muscles (14 ,15). The leading com-
pounds targeted exon 51, whose skipping is predicted to 
restore the ORF in the highest portion of DMD patients 
(around 10-15%). Subsequent phase 2 dose-escalation 
studies (16, 17) were also promising, as they seemed to 
provide not only assurances of good tolerability of these 
compounds, but also biochemical evidence of dystrophin 
restoration and encouraging stabilization or improvement 
of some functional outcome measures. Unfortunately, in 
the years immediately following these exciting break-
throughs, the enthusiasm of the DMD community was 
thwarted. An international, multi-center phase 3 trial of 
drisapersen (clinicaltrials.gov NCT01254019), the 2’-O-
methyl AON for the skipping of exon 51 developed by 
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Biomarin/Prosensa, failed to achieve a significant clinical 
benefit (the results have not yet been published). While 
more partially encouraging data came from a phase 2b 
extension study (18), the company decided to discontinue 
the drisapersen development program. These events have 
triggered a lively debate (19, 20) about several contro-
versial aspects of exon skipping treatments, such as the 
difficulty to accurately measure efficacy of treatments 
both at the molecular (21) and clinical level (22), and the 
amount of dystrophin needed to actually obtain a clinical 
benefit (23). As for eteplirsen, the morpholino AON for 
the skipping of exon 51 developed by Sarepta, phase 3 
studies are still underway (NCT02255552), but interest-
ing data have derived from a small but prolonged phase 
2b extension study (24). Clinical data from this open-la-
bel study, also corroborated by comparison to a mutation-
matched external natural history control group (25), seem 
to support stabilization of ambulatory function in 12 pa-
tients. Unfortunately, data regarding dystrophin quantifi-
cation in several longitudinal muscle biopsies in the same 
study indicate less abundant protein expression increase 
than suggested by earlier studies, and have been the ob-
ject of controversy (26, 27). Despite these uncertainties, 
the Food and Drugs Administration has recently granted 
accelerated approval to eteplirsen in the United States 
of America, recognizing that a demonstrated increase in 
a biologically relevant biomarker, i.e. dystrophin, how-
ever small, may reasonably be expected to benefit DMD 
patients (6). Hopefully, successful confirmatory trials 
will allow the clinical efficacy of exon skipping AONs 
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Figure 1. Flow diagram of genetic diagnosis in DMD, highlighting indicated molecular assays (blue circles) and cor-
responding possible findings (red rectangles), leading to further assays, or, in some cases, to established amenability 
for molecular treatments (green rectangles).
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to be established without ambiguity. Clinical trials of 
AONs targeting exons other than 51 are underway (e.g. 
NCT02310906 and  NCT02500381), and new genera-
tions of AONs are being experimented at the preclinical 
stage  (28, 29), so that exon skipping still represents a 
promise of future effective treatments for a large portion 
of DMD patients.
Stop codon readthrough 
compounds
About 15% of the causative mutations in DMD are 
single nucleotide substitutions introducing a prema-
ture termination codon (nonsense mutations) (10). This 
causes the ribosomial complex to stall during translation, 
usually resulting in nonsense-mediated decay of the tran-
script and absence of dystrophin (30). However, nonsense 
mutations may also be observed in association with BMD 
or intermediate phenotypes, probably due to naturally oc-
curing alternative splicing of in-frame exons (31). Fur-
thermore, ribosomes may be pharmacologically induced 
to “read through” premature stop codons, and continue 
downstream translation, giving rise to normal dystrophin. 
Aminoglycosides were demonstrated to effectively pro-
mote dystrophin expression in the mdx mouse model, 
which carries a nonsense mutation in exon 23 (32), but 
human trials were hindered by excessive toxicity (33, 34). 
The pharmaceutical company PTC Therapeutics has de-
veloped a small molecule compound, ataluren, which has 
been shown to maintain the same nonsense readthrough 
effect as aminoglycosides (although the exact molecular 
mechanism has not been completely cleared) (35) with a 
more favorable tolerability profile. After proof-of-concept 
studies in animal models (36) and phase 1 trials showing 
no relevant safety issues (37), ataluren was dosed in DMD 
in a first phase 2a study with further reassurance of safety, 
and encouraging results (38). The results of a larger phase 
2b trial were controversial (39), as the primary endpoint 
(48-week change in the 6 minute walk test [6MWT]) was 
not achieved, and better ambulation outcomes were un-
expectedly observed in a 10, 10, 20 mg/kg than 20, 20, 
40 mg/kg study arm. Unfortunately, quantitative assess-
ments of dystrophin restoration in muscle tissue from 
participant biopsies were hindered by technical issues in 
this study. However, indications of efficacy in the phase 
2b study were sufficient for the European Medicines 
Agency to issue a conditional approval for the marketing 
of ataluren in European Union countries in 2014 (5), with 
the obligation on the company’s part to conduct a phase 3 
confirmatory study, the results of which (NCT01826487) 
have recently been released online (http://ir.ptcbio.com/
releasedetail.cfm?ReleaseID=936905) although not yet 
published as a peer-reviewed article. While the primary 
endpoint of change in the 6MWT still remained elusive, 
pre-specified subgroup analyses and meta-analyses in 
conjunction with the previous phase 2b study showed a 
clear, although not dramatic drug effect in delaying the 
deterioration of ambulatory function in DMD. Currently, 
ataluren is prescribable to DMD patients with nonsense 
mutations who are older than 5 years and ambulatory in 
several European countries. The continued development 
of the nonsense readthrough strategy will hopefully pro-
vide a solid therapeutic option for a relevant subgroup of 
DMD patients.
“Exon snipping”: mutation-specific 
gene editing
Clustered regularly interspaced short palindromic 
repeats (CRISPR)/CRISPR-associated (Cas) systems are 
an adaptive immune defense evolved in bacteria and ar-
chaea, which uses short RNAs for the degradation of for-
eign nucleic acids. In 2013, several independent groups 
reported the successful reprogramming of CRISPR-Cas9 
to cut DNA at any site of choosing in eukaryotic cells, 
by coupling it with a strand of guide RNA (gRNA) with 
a custom sequence (40-42). This breakthrough invention 
has revolutionized molecular biology with its myriad po-
tential applications. Applied to DMD, the CRISPR-Cas9 
approach has been aptly named “exon snipping” (43), 
in analogy with the “exon skipping” obtained by AON 
targeting of mRNA. “Exon snipping” would primarily 
consist in excising an in-frame exon containing a small 
nonsense or frameshifting mutation, as successfully dem-
onstrated with adeno-associated virus (AAV) delivery in 
the mdx murine model (44, 45), or, alternatively, in excis-
ing specific exons in order to restore the ORF in the case 
of large rearrangements (deletions or duplications) (46). 
The main drawbacks of this approach are represented by 
the challenges of AAV vector delivery in humans, and the 
fear of off-target effects. Nevertheless, the versatility and 
wide applicability of this technology to virtually every 
DMD causing mutation makes it one of the most exciting 
and promising novel approaches to molecular therapy of 
DMD.
Conclusions
The advancements of molecular treatments described 
above have made reaching a precise genetic diagnosis in 
DMD more and more important over the last few years. 
Currently, DMD patients with deletions bordering exon 
44, 45, 51 or 53 bordering may be eligible for recruitment 
in one of several ongoing clinical trials of exon skipping. 
Patients eligible for exon 51 skipping may be treated with 
commercialized eteplirsen in the United States (Exondys 
Luca Bello and Elena Pegoraro
126
51®, Sarepta Therapeutics, Cambridge, MA, USA). Pa-
tients in whom MLPA (or other equivalent quantitative as-
says for large deletions/duplications) tests negative, should 
be studied with DMD gene sequencing in order to be able 
to provide genetic counseling to the family, and because 
patients with nonsense mutations may be eligible for treat-
ment with ataluren, commercialized as Translarna® in the 
European Union (PTC Therapeutics, South Plainfield, NJ, 
USA), or within future clinical trials. While the advance-
ment of these treatments has been painstakingly slow in 
the eyes of DMD patients and their families, who struggle 
every day against the progression of this disabling disease, 
there are reasons to hope that the experience gathered in de-
signing better clinical trials, as well as an increasing number 
of novel drugs in the pipeline of preclinical research, will 
bring on a faster and more effective translation of scientific 
findings into benefit for patients in the upcoming years.
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